This well-characterized kinase cascade is frequently triggered by oncogenic mutations (mostly RAS or RAF) or by growth factor signaling (e.g., EGFR), and its prominent role in many different types of cancers is reflected by the number of mitogen-activated protein kinase (MAPKK, aka MEK)-inhibitors currently under clinical investigation [24]. The gene discussed is MAP2K7; the disease is cancer.